Kornimate/medical-research-clean huggingface dataset:
cognitive profile of patients at the sagol center for hyperbaric medicine and research

Conditions: TBI (Traumatic Brain Injury); Stroke; Fibromyalgia; Aging

Summary: in the investigator's institute there is ongoing treatment of different patients with cognitive deficits using hyperbaric oxygen therapy (hbot). these patients undergo neuro-cognitive function computerized tests before and after treatment. the aim of this study was to retrospectively evaluate the cognitive changes before and after hbot in different patients populations.

retrospective analysis of patients suffering from chronic neuro-cognitive deficits due to different conditions, treated at sagol center for hyperbaric medicine and research, shamir (assaf harofeh) medical center, israel patients included if they had at least two neurocognitive tests, before and after hyperbaric oxygen therapy (hbot). the study was approved by the institutional review board of the hospital. patients were treated with 40-60 daily hyperbaric sessions, 5 days per week. each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ata.

Eligibility criteria:
inclusion criteria: * patients included if they completed at least two neuro-cognitive computerized tests, before and after hbot exclusion criteria: * patients who were not able to complete two cognitive tests
effects of endotracheal tube cuff pressure control on microaspiration of gastric contents

Conditions: Mechanical Ventilation Complication; Ventilator Associated Pneumonia; Nursing Caries; Aspiration, Respiratory

Summary: the purpose of study is to determine effects of three different et cuff pressure control on microaspiration of the stomach contents.

in the study, et cuff pressure control will be provided with pilot balloon fingers (control group), intermittent with a manometer (study group 1) and continuously with a smart cuff manager (study group 2). to assess the effect of different ett cuff pressure control on microaspiration of the stomach contents, the pepsin level will be measured during deep tracheal secretions. the samples will be examined in the first four hours after intubation, all secretions collected up to the 24th hour of intubation after first sample intake and all secretions collected between 24-48 hours after intubation. pepsin level will be considered as positive for cut-off point. in addition, the effect of different ett cuff pressures control on the incidence of vap will be examined.

Eligibility criteria:
inclusion criteria: * volunteering of the patient or relatives who will participate in the study, * patients who require mechanical ventilation support with endotracheal tube supply for 48 hours. exclusion criteria: * patients who are contraindicated in giving a semi-fowler position, * patients with enteral nutrition contraindications, * patients connected to mechanical ventilators for more than 48 hours, * patients with tracheostomy, * patients admitted to icu for gastroesophageal reflux disease, aspiration pneumonia or suspicion, * nasal endotracheal intubation.

Keywords: intensive care
peri-articular injection utilizing a pain cocktail with and without exparel

Conditions: Total Knee Arthroplasty; Pain Management

Summary: a prospective, randomized control study will be conducted to compare postoperative pain control in a series of patients treated with either: 1. a local cocktail. 2. a local cocktail plus exparel. 3. marcaine plus exparel prior to wound closure following knee arthroplasty.

as an alternative to the various injection cocktails, exparel, a liposomal-coated bupivicaine, was introduced as a long-acting form of bupivicaine, a local anesthetic. this new technology has been utilized by numerous orthopedic joint surgeons. since its introduction there have been studies showing varying results in terms of postoperative pain control. therefore, it is our purpose to conduct a prospective, randomized control study to compare postoperative pain control in a series of patients treated with either: 1. a local cocktail. 2. a local cocktail plus exparel. 3. marcaine plus exparel prior to wound closure following knee arthroplasty. methodology subjects will be randomized preoperatively into three different groups on total knee subjects done at three different facilities. this study is single blinded study. the visual pain scale from 1-10 will be used to determine pain control at 3, 12, 24, and 48 hour time intervals postoperatively. postoperative narcotic use will also be monitored at the same time intervals.

Eligibility criteria:
inclusion criteria: * institutional review board (irb) review has been conducted and approval of the study has been obtained * the subject underwent a primary total knee replacement under adductor canal block with general anesthesia exclusion criteria: * the subject is a minor * the subject is on chronic narcotics * the subject has an indwelling pain pump * the subject is having a knee revision surgery * the subject is having a partial knee replacement * the subject has a history of sepsis in a previously replaced joint * the subject has back pain * the subject has radicular pain * the subject suffers from depression * the subject has fibromyalgia * the subject is currently involved in any personal injury litigation, medical-legal, or worker's compensation claims

Keywords: total knee arthroplasty total knee replacement exparel cocktail injection pain management
use of a colorectal cancer screening decision support tool in primary care

Conditions: Colorectal Cancer Control and Prevention; Colorectal Cancer Screening; Shared Decision Making; Decision Aid

Summary: the research question we pose is, does a colorectal cancer (crc) screening decision support tool offered in advance of primary care visits increase crc screening completion rates? our work aims to answer this question by evaluating the effectiveness of an mgb decision support tool to 1) promote informed decisions about crc screening for average risk patients ages 45-75, 2) deploy a decision support tool as part of a primary care bundle questionnaire, and 3) support patients in completing their preferred method of crc screening.

as part of usual care, a crc screening electronic decision support tool developed by mass general brigham has been integrated into epic. this decision support tool is part of routine clinical care and is sent electronically to patients aged 45-75 who receive the annual visit primary care screening bundled questionnaire in advance of their annual visit. patients complete the tool on patient gateway prior to the visit or via an ipad at the visit. the decision support tool guides patients through the crc screening options (e.g., fit, colonoscopy, cologuard) to help them select their preferred screening method. as part of routine care, the patient will be prompted to complete the tool as part of the bundled questionnaire, and the results will be available in the epic encounter in the screenings tab with the other screening bundle responses. the primary care clinician can then discuss the options and/or screening preference with the patient. depending on what the patient and clinician decide, a crc screening test may be ordered for the patient. as a secondary outcome, a random sample of 1000 patients will be surveyed to understand their involvement in the decision making process and 300 providers will be surveyed to understand how the decision tool impacted the conversation with the patient. the irb to conduct surveys of patients and providers was approved by the mass general brigham irb (protocol # 2024p002568).

Eligibility criteria:
inclusion criteria: adults aged 45-75 overdue for crc screening at average risk of crc have an annual visit scheduled with participating practices exclusion criteria: * high risk of crc

Keywords: colorectal cancer screening shared decision making electronic health record randomized controlled trial decision tool
legal-education plus trauma-informed therapy to improve community acceptance and reintegration of repentant terrorists in nigeria

Conditions: Trauma, Psychological; Legal Education

Summary: terrorism is an issue of global concern, and reintegrating repentant terrorists, including their families, has often proved challenging considering the damages done by the terrorist group. despite boko haram atrocities in nigeria, the focus seems directed toward the repentant terrorists with limited attention to the communities, the trauma they suffered, and their involvement in the design of reintegration programmes. there is also limited community awareness of legal support channels to foster positive reintegration (ike et al., 2021). the implication is that it risks undermining the social context that informs successful reintegration, improves acceptance, and reduces reoffending. however, there appears to be limited research on this important policy problem in nigeria. our study proposes to fill this gap by contributing to the research initiative through a novel cross-disciplinary intervention drawing on law and psychology entitled legal education plus trauma-informed therapy (letit) to improve community acceptance and reintegration of repentant terrorists in nigeria.


Eligibility criteria:
inclusion criteria: * ages 18 - 85 years * able to give consent * able to understand and speak english * score a minimum of 5 on trauma screening questionnaire * residents of designated communities of intervention (adamawa, maiduguri, and plateau states) * available for the study and follow up at 3- and 6-months post-intervention exclusion criteria: * less than 18 or above 85 years * unable to give consent * clinically diagnosed with severe ptsd/suicidal ideations or undergoing treatment * temporary or non-residents who are unlikely to be available for follow up
an efficacy and safety study of telaprevir in patients with genotype 1 hepatitis c infection after liver transplantation

Conditions: Chronic Hepatitis C Virus (HCV) Infection

Summary: the purpose of this study is to evaluate the effectiveness of telaprevir in combination with peg-ifn-alfa-2a and ribavirin in stable liver transplant patients with chronic hepatitis c virus (hcv) genotype 1.

this is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic hcv infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with peg-ifn-alfa-2a and ribavirin followed by 36 weeks of treatment with peg-ifn-alfa-2a and ribavirin alone. the total treatment duration will be 48 weeks. safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination.

Eligibility criteria:
inclusion criteria: * first time liver transplant recipient whose primary pre-transplant diagnosis was chronic hepatitis c genotype 1 * more than 6 months to 10 years post-liver transplant * patient did or did not receive treatment for hcv prior to liver transplantation * patient must agree to have a liver graft biopsy during the screening period unless they had a biopsy within three months of the screening period (for patients between 6 months and one year post transplant) or within six months of the screening period (for patients who are more than one year post transplant) * a female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of ribavirin exclusion criteria: * patient is currently infected or co-infected with hcv of another genotype than genotype 1 * patient received treatment for hepatitis c following liver transplantation * patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis c * patient with human immunodeficiency virus or hepatitis b virus co-infection * patient with active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma or hepatocellular carcinoma)

Keywords: chronic hcv infection genotype 1 chronic hcv liver transplantation hepatitis c hep c hcv telaprevir pegylated-interferon-alfa-2a ribavirin
critical state of "remission-recurrence" of ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this study will recruit 100 patients with ulcerative colitis in remission for a 6-month non intervention follow-up observation. during the study, their conditions will be recorded truthfully, including general information, disease-related symptoms and signs, inflammatory bowel disease questionnaire, anxiety self-assessment scale, depression self-assessment scale, etc., every month. collect blood, urine, and stool samples from patients every month for examination. follow up for each subject until their condition recurs.


Eligibility criteria:
inclusion criteria: * patients who meet the criteria based on the clinical characteristics of ulcerative colitis patients in the "remission recurrence" critical state, combined with clinical symptoms, are diagnosed with ulcerative colitis through imaging, endoscopy, laboratory, and histopathological examinations; * patients with comprehensive laboratory testing indicators. exclusion criteria: * patients with incomplete case information records; * patients who have not completed serological tests; * complications including intestinal obstruction, intestinal perforation, toxic megacolon, and severe local stenosis; * diagnosed or suspected patients with coexisting uncertain colitis, infectious or ischemic colitis; * patients with coexisting local or systemic infections, any malignant diseases, or autoimmune diseases; * merge primary diseases such as respiratory, circulatory, neurological, endocrine, and hematological disorders; * individuals at risk of developing cancer; * regnant or lactating women.
pet-ct for squamous cell carcinoma (scc) of the neck nodes unknown primary malignancy

Conditions: Squamous Cell Cancer

Summary: patients with squamous cell cancer of neck nodes but unknown primary will have a pet-ct scan prior to biopsies. the utility of pet-ct will be determined in this subset of patients.


Eligibility criteria:
inclusion criteria: * squamous cell cancer of neck nodes with unknown primary site exclusion criteria: * unable to tolerate pet-ct * unable to undergo examination under anaesthesia

Keywords: squamous unknown primary patients with squamous cell cancer neck nodes
international study of comparative health effectiveness with medical and invasive approaches-left ventricular dysfunction trial

Conditions: Coronary Artery Disease; Cognitive Impairment; Heart Failure

Summary: the ischemia-hf trial will randomize participants with multivessel coronary artery disease (cad) with ejection fraction (ef) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (gdmt):coronary artery bypass grafting (cabg):percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction (lvef) ≤ 40% within prior 6 months (any local measurement, made within the past 6 months using echocardiography, multigated acquisition (muga), computed tomography (ct) scanning, magnetic resonance imaging (mri), or ventricular angiography is acceptable, provided no subsequent measurement above 40%) * participants with multivessel cad (defined as severe 3 vessel disease or 2 vessel disease including left anterior descending (lad) artery disease) on coronary ct angiography (ccta) or invasive coronary angiography * cad amenable to either pci or cabg as determined by the local heart team * participant is willing to comply with all aspects of the protocol, including adherence to the assigned strategy, medical therapy and follow-up visits * participant is able and willing to give written informed consent exclusion criteria: * decompensated heart failure or cardiogenic shock in the past 48 hours prior to randomization * concomitant significant valvular heart disease requiring surgery * prior cardiac surgery * dementia with loss of capacity to consent (clinically evident or previously diagnosed) * stroke within the previous 6 months or spontaneous intracranial hemorrhage at any time * history of noncompliance with medical therapy * life expectancy less than the duration of the trial due to non-cardiovascular comorbidity * pregnancy (known to be pregnant; to be confirmed before randomization, if applicable)

Keywords: coronary artery disease heart failure ejection fraction
low-dose statins and nutraceuticals in high-intensity statin-intolerant patients

Conditions: Coronary Artery Disease

Summary: the primary objective of this study is to compare the efficacy and tolerability of low-dose statin therapy vs. the association between a low-dose statin and a nutraceutical-based protocol in high-dose statin-intolerant patients with coronary artery disease deemed to be at high-risk.

several clinical trials have shown that in patients with atherosclerotic cardiovascular disease, reduction of low-density lipoprotein (ldl) level with a beta-hydroxy-beta-methylglutaryl coenzyme a reductase inhibitor (ie, statin) is associated with significant reductions in both mortality rate and major cardiac events. accordingly, current guidelines recommend that high-intensity statin therapy-such as rosuvastatin 20 to 40 mg or atorvastatin 80 mg-should be used to achieve at least a 50% reduction in ldl cholesterol unless otherwise contraindicated. in real world clinical practice, however, high-intensity statin treatment is often discontinued by patients due to side effects. as alternatives, nonstatin drugs, such as ezetimibe, are often prescribed in association with moderate-to-low intensity statin. it remains unknown, however, whether the association between moderate-to-low intensity statin therapy and and nutraceuticals (i.e. compounds derived from foods with cholesterol lowering actions) can have a therapeutic role in high-intensity statin-intolerant patients.

Eligibility criteria:
inclusion criteria: * angiographically-proven coronary artery disease * recent (\<12 months) percutaneous coronary intervention * class i indication to receive statin treatment to achieve the ldl cholesterol goal of \<70 mg/dl * able to understand and willing to sign the informed consent form exclusion criteria: • women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before ct

Keywords: coronary artery disease, nutraceuticals, statins
dysfunctional uterine bleeding after tubal sterilization

Conditions: Contraception; Dysfunctional Uterine Bleeding

Summary: in this study, the investigators will compare the frequency and amount of bleeding after tubal sterilization and salpingectomy

dysfunctional uterine bleeding is common after tubal sterilization. the investigators will compare the frequency and amount of bleeding after two techniques eithe tubal sterilization by pomeroy's method during cesarean section or complete salpingectomy

Eligibility criteria:
inclusion criteria: * age 20-40 * patient completed her family * patient on cesarean delivery exclusion criteria: * tubal sterilization by other methods * salpingectomy by laparoscopy * patient wishing fertility

Keywords: dysfunctional uterine bleeding tubal sterilization salpingectomy cesarean section
monitoring patient cerebro-spinal fluid drainage with an ultrasonic flow sensor

Conditions: Hydrocephalus

Summary: the study hypothesis is that an ultrasonic flow sensor can accurately measure flow in hydrocephalic shunts. the ultrasonic sensor will measure cerebro-spinal fluid drainage in hydrocephalus patients with external ventriculostomies and extra-ventricular drainage systems. the sensor measurements will be compared with the volume of fluid collected by the drainage bag. after a 24-hour measurement period, the doctor will change the drainage bag position to simulate the patient sitting up and leaning back, to see if this temporarily stops flow through the drainage line. this data will show whether the sensor accurately measures typical drainage flows seen in hydrocephalus patients. this research will help develop an implantable flow monitor for pediatric hydrocephalus patients.


Eligibility criteria:
inclusion criteria: * age: newborn through age 20 * diagnosed with hydrocephalus * instrumented with an extra-ventricular drainage line exclusion criteria: * age: older than age 20 * not diagnosed with hydrocephalus * not instrumented with an extra-ventricular drainage line

Keywords: hydrocephalus shunt dysfunction shunt flow
a study of wrist actigraphy in overweight and obese adults with sleep disorders

Conditions: Sleep Disorders

Summary: 70 overweight or obese adults with sleep disorders will be recruited for this study, in which the investigators aim to compare wrist actigraphy with polysomnography (psg) for sleep monitoring. it is to evaluate the applications of jawbone up2 with the sleep parameters derived from this actigraphy.

as an observation study, it will recruit 70 overweight or obese patients with sleep disorders who meet the selection criteria: clinical records and ais at a tertiary hospital. the patients will sign the informed consent form. the involved patients and doctors will receive related training. these patients will receive the sleep monitoring from 21:00 to 6:00 in sleep monitoring laboratory in ruijin hospital. they will receive the psg and jawbone up 2 sleep monitoring at the same time. sleep parameters derived from actigraphy and psg will be compared in multiple night recordings such as total sleep time, wake after sleep onset, sleep onset latency, awakening, sleep efficiency, total time in bed,. the aim is to assess the validation of actigraphy in overweight or obese patients with sleep disorders.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * have one or more sleep disorders such as consecutive snoring, insomnia, sleep apnea, narcolepsy, delayed sleep phase syndrome * athens insomnia scale (ais)\>6 * bmi\>25 * agree to participate in the study and have signed the inform consent form exclusion criteria: * terminal illness * physically-challenged and paralyzed patients * intend to receive selective surgery, to get pregnancy and breast feeding in three months * long-term use of the sleeping pills * hearing loss or severe visual disorder; * mental disorders * dementia or communication disorders * unable to complete an all night sleep monitoring

Keywords: actigraphy overweight and obese adults sleep disorders